PerkinElmer
check quantity

MMPSense 645 FAST Fluorescent Imaging Agent

Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications. 

You successfully added item(s) to your cart

For laboratory use only. This product is intended for animal research only and not for use in humans.

Part Number
List Price
Your Price
Quantity
NEV10100
710.00 USD
more
Buy Now

Please enter valid quantity

Please login to add favorites

NULL OR EMPTY CART

Detail Information

MMPSense® 645 FAST in vivo reagent is a member of a family of activatable fluorescent imaging agents comprising a novel architecture termed F.A.S.T. (Fluorescent Activatable Sensor Technology), that confers an improved pharmacokinetic profile with earlier imaging time points. This architecture offers higher target specific signal with reduced background while also reducing the optimal imaging time after injection. 

MMPSense 645 FAST is a matrix metalloproteinase (MMP) activatable agent that is optically silent upon injection and produces fluorescent signal after cleavage by disease related MMP’s. Activation can occur by a broad range of MMP’s including MMP 2, 3, 7, 9, 12, and 13. 

MMP activity is involved in many disease-related processes including cancer progression, invasion and metastasis, rheumatoid arthritis, pulmonary diseases and areas of cardiovascular disease. MMPSense 645 FAST fluorescent imaging agent may be used to monitor the progression of these diseases or to evaluate the potential therapeutic efficacy of drugs targeting the underlying mechanisms involved in these diseases.

Specifications

Fluorescent Agent Type Activatable
Optical Imaging Classification Fluorescence Imaging
Product Brand Name MMPSense
Quantity in a Package Amount 1.0 Units
Shipping Condition Blue Ice
Therapeutic Area Atherosclerosis, Arthritis, Inflammation, Oncology/Cancer
Unit Size 1 Vial (10 doses)
Wave Length 645 nm
Resources, Events & More
  • All

Technical Note

MMPSense 645 FAST (Data Sheet)

MMPSense 645 FAST a member of a family of activatable fluorescent imaging agents comprising a novel architecture termed F.A.S.T. (Fluorescent Activatable Sensor Technology), that confers an improved pharmacokinetic profile with earlier imaging time points. This architecture offers higher target specific signal with reduced background while also reducing the optimal imaging time after injection.

PDF 358 KB